Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 4/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508358 | 1.00 | ESR1 (0.43) | ESR1AAK1MAPK1PPARGPPARD | |
| SCHEMBL3685186 | 0.80 | ESR1 (0.47) | ESR1MAPK1PPARDALDH1A1 | |
| SCHEMBL13508359 | 0.80 | ESR1 (0.47) | ESR1MAPK1PPARDALDH1A1 | |
| SCHEMBL13508360 | 0.77 | LMNA (0.50) | ESR1MAPK1PPARDALDH1A1 | |
| SCHEMBL4855183 | 0.76 | ESR1 (0.51) | ESR1AAK1MAPK1PPARGNLRP3 | |
| SCHEMBL5974797 | 0.74 | ESR1 (0.55) | ESR1PPARDVDRALDH1A1 | |
| SCHEMBL3696699 | 0.73 | ESR1 (0.46) | ESR1PPARDALDH1A1 | |
| SCHEMBL12059023 | 0.73 | ESR1 (0.54) | ESR1PPARDVDRALDH1A1 | |
| SCHEMBL14527871 | 0.72 | ESR1 (0.53) | ESR1MAPK1PPARDVDRALDH1A1 | |
| SCHEMBL1549625 | 0.72 | VDR (0.45) | ESR1PPARDVDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | ESR1 1864/4885AAK1 1952/4885MAPK1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.